Selection of K65R Mutation in HIV-2-Infected Patients Receiving Tenofovir-Containing Regimen

Wainberg M.A. , Miller M.D. , Quan Y. , Salomon H. , Mulato A.S. , Lamy P.D. , Margot N.A. , Anton K.E. , & Cherrington J.M. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Therapy 1999; 4: 87–94.

Lanier E. , Irlbeck D. , Ross L. , Gerondelis P. , Underwood M. , Parkin N. , Shappey C. , & St Clair M. Prediction of NRTI options by linking reverse transcriptase genotype to phenotype breakpoints. 10th Conference on Retroviruses & Opportunistic Infections, 10–14 February 2003, Boston, Mass., USA. Abstract 586.

Parikh U. , Koontz D. , Hammond J. , Bacheler L. , Schinazi R. , Meyer P. , Scott W. , & Mellors J. K65R: a multi-nucleoside resistance mutation of low but increasing frequency. 12th International HIV Drug Resistance Workshop, 10–13 June 2003, Los Cabos, Mexico. Abstract 136.

Cundy K.C. , Sueoka C. , Lynch G.R. , Griffin L. , Lee W.A. , & Shaw J. P. Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Antimicrobial Agents & Chemotherapy 1998; 42: 687–690.

Margot N.A. , Isaacson E. , McGowan I. , Cheng A.K. , Schooley R.T. , & Miller M.D. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002; 16: 1227–1235.